Octreotide(Peptron, Inc.)(Octreotide(Peptron, Inc.)) - 药物靶点：SSTR_在研适应症：肢端肥大症，类癌_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Octreotide controlled-release、SR Octreotide

+ [1]

靶点

SSTR

作用方式

激动剂

作用机制

SSTR激动剂(生长抑素受体激动剂)

治疗领域

肿瘤神经系统疾病内分泌与代谢疾病+ [2]

在研适应症

肢端肥大症类癌

非在研适应症-

原研机构

Peptron, Inc.

在研机构

Peptron Ltd.

非在研机构

Peptron, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C49H66N10O10S2

InChIKeyDEQANNDTNATYII-OULOTJBUSA-N

CAS号83150-76-9

Sequence Code 19721

关联

5

项与 Octreotide(Peptron, Inc.) 相关的临床试验

CTRI/2023/06/054062

/ Not yet recruitingN/A

A three armrandomized control trial to study the efficacy of flap fixation with suturesand conventional closure plus intravenous octreotide in comparison withconventional skin closure in the reduction of post mastectomy seromaformation

开始日期2023-07-03

申办/合作机构-

NCT05340192

/ Completed临床1期IIT

Effect of Octreotide on Saliva

The purpose of this study is to determine the effect of Octreotide on saliva enzymes. The study team hypothesizes that Octreotide will decrease the levels of certain proteins, specifically the metalloproteinase family.

开始日期2019-09-24

申办/合作机构

Duke University

EUCTR2014-000256-28-CZ

/ Not yet recruiting临床2期

A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the Treatment of Metastatic Breast Cancer.

开始日期2014-08-21

申办/合作机构

GlaxoSmithKline Research & Development Ltd.

100 项与 Octreotide(Peptron, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Octreotide(Peptron, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Octreotide(Peptron, Inc.) 相关的专利（医药）

登录后查看更多信息

4,990

项与 Octreotide(Peptron, Inc.) 相关的文献（医药）

2025-02-01·Journal of NeuroInterventional Surgery

Technique and impact on first pass effect primary results of the ASSIST global registry

Article

作者: Defreyne, Luc ; Cioltan, Andreea ; Vollherbst, Dominik F ; Calleja Bonilla, Angel ; Price, Lori Lyn ; Miralbés, Salvador ; Chaubal, Varun ; Liebeskind, David S ; Galván-Fernandez, Jorge ; Rayes, Mahmoud ; Vega, Pedro ; Naravetla, Bharath ; Jayaraman, Mahesh V ; Gupta, Rishi ; Khaldi, Ahmad ; McTaggart, Ryan A ; Dhondt, Elisabeth ; Majjhoo, Aniel Q ; Murias, Eduardo ; Spiotta, Alejandro M ; Loehr, Christian ; Lin, Eugene ; Martínez-Galdámez, Mario ; Möhlenbruch, Markus A

BackgroundPatients treated with mechanical thrombectomy (MT) for acute ischemic strokes from large vessel occlusion (LVO) have better outcomes with effective reperfusion. However, it is unknown which technique leads to better technical and clinical success. We aimed to determine which technique yields the most effective first pass reperfusion during MT.MethodsIn a prospective, multicenter global registry we enrolled patients treated with operator preferred MT technique at 71 hospitals from January 2019 to January 2022. Three techniques were assessed: SR Classic with stent retriever (SR) and balloon guide catheter (BGC); SR Combination which employed SR with contact aspiration with or without BGC; and direct aspiration (DA) with or without BGC. The primary outcome was achieving an expanded Thrombolysis In Cerebral Infarction (eTICI) score of 2c or 3 on the first pass, with the primary technique as adjudicated by core lab. The primary clinical outcome measure was a 90-day modified Rankin Scale (mRS) score of 0–2.ResultsA total of 1492 patients were enrolled. Patients treated with SR Classic or SR Combination were more likely to achieve first pass eTICI 2c or 3 reperfusion (P=0.01). There was no significant difference in mRS 0–2 (P=0.46) or safety endpoints.ConclusionsThe use of SR Classic or SR Combination was more likely to achieve first pass eTICI 2c or 3 reperfusion. There were no significant differences in clinical outcomes and safety endpoints.

2024-12-01·Stroke and Vascular Neurology

Prevalence, risk factors and prognostic value of atrial fibrillation detected after stroke after haemorrhagic versus ischaemic stroke

Article

作者: Jia, Jiaokun ; Wang, Dandan ; Li, Zixiao ; Yang, Kaixuan ; Zhang, Jia ; Lu, Jingjing ; Zhao, Xingquan ; Wang, Yongjun ; Gu, Hongqiu ; Guo, Jiahuan ; Liu, Yanfang

Background and objectivesPrior evidence suggests that atrial fibrillation detected after stroke (AFDAS) is distinct from known atrial fibrillation (KAF), with particular clinical characteristics and impacts on outcomes in ischaemic stroke. However, the results remained inconsistent in ischaemic stroke, and the role of AFDAS in haemorrhagic stroke remains unclear. Therefore, we aimed to estimate the prevalence, risk factors and prognostic value of AFDAS in haemorrhagic stroke in comparison with ischaemic stroke.MethodsThis was a multicentre cohort study. Patients who had an ischaemic and haemorrhagic stroke hospitalised in the Chinese Stroke Center Alliance hospitals were enrolled and classified as AFDAS, KAF or sinus rhythm (SR) based on heart rhythm. Univariate and multivariate logistic regression analyses were used to assess the prevalence, characteristics, risk factors and outcomes of AFDAS, KAF and SR in different stroke subtypes.ResultsA total of 913 163 patients, including 818 799 with ischaemic stroke, 83 450 with intracerebral haemorrhage (ICH) and 10 914 with subarachnoid haemorrhage (SAH), were enrolled. AFDAS was the most common in ischaemic stroke. There were differences in the risk factor profile between stroke subtypes; older age is a common independent risk factor shared by ischaemic stroke (OR 1.06, 95% CI 1.06 to 1.06), ICH (OR 1.08, 95% CI 1.07 to 1.09) and SAH (OR 1.07, 95% CI 1.05 to 1.10). Similar to KAF, AFDAS was associated with an increased risk of in-hospital mortality compared with SR in both ischaemic stroke (OR 2.23, 95% CI 1.94 to 2.56) and ICH (OR 2.84, 95% CI 1.84 to 4.38).DiscussionThere are differences in the prevalence, characteristics and risk factors for AFDAS and KAF in different stroke subtypes. AFDAS was associated with an increased risk of mortality compared with SR in both ischaemic stroke and ICH. Rhythm monitoring and risk factor modification after both ischaemic and haemorrhagic stroke are essential in clinical practice. More emphasis and appropriate treatment should be given to AFDAS.

2024-11-01·Combinatorial Chemistry & High Throughput Screening

Network Pharmacology and Molecular Docking Analysis on Mechanisms of Scutellariae Radix in the Treatment of Cerebral Ischemia-reperfusion Injury

Article

作者: Bai, Lu ; Yang, Yang ; Yuan, Wenting ; Hou, Yongqiang ; Duan, Shiwan ; Xu, Mengrong ; Feng, Yue ; Fang, Fei

Background:Multiple brain disorders are treated by Scutellaria Radix (SR), including cerebral ischemia-reperfusion (CI/R). However, more studies are needed to clarify the molecular mechanism of SR for CI/R.Methods:The active substances and potential targets of SR and CI/R-related genes were obtained through public databases. Overlapping targets of SR and CI/R were analyzed using proteinprotein interaction (PPI) networks. GO and KEGG enrichment analyses were performed to predict the pathways of SR against CI/R, and the key components and targets were screened for molecular docking. The results of network pharmacology analysis were verified using in vitro experiments.Results:15 components and 64 overlapping targets related to SR and CI/R were obtained. The top targets were AKT1, IL-6, CAS3, TNF, and TP53. These targets have been studied by GO and KEGG to be connected to a number of signaling pathways, including MAPK, PI3K-Akt pathway, and apoptosis. Molecular docking and cell experiments helped to further substantiate the network pharmacology results.Conclusion:The active compound of SR was able to significantly decrease the apoptosis of HT22 cells induced by OGD/R. This finding suggests that SR is a potentially effective treatment for CI/R by modulating the MAPK and PI3K-Akt pathways.

100 项与 Octreotide(Peptron, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00442	-	-	DB00104

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肢端肥大症	临床2期	-	Peptron, Inc.	2021-04-30
类癌	临床2期	-	Peptron, Inc.	2021-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2015	N/A	胸腺上皮肿瘤	-	Octreotide/lanreotide plus prednisone	(遞顧製鹽簾願衊願淵窪) = 膚製壓襯壓簾齋獵餘鑰鑰簾獵齋顧範鏇膚範願 (遞鏇齋繭壓醖壓淵製鏇 ) 更多	积极	2015-05-20
LARCID (ASCO_GI2012)	临床3期	结直肠癌辅助 \| 一线	139	Octreotide LAR	(鬱顧襯積繭簾網網構齋) = 鹹構獵醖齋壓餘鑰艱糧鏇壓遞構糧醖餘範膚糧 (醖遞憲憲網糧壓醖鹽夢 )	不佳	2012-02-01
				long-acting release octreotide (Physician's treatment of choice)	(鬱顧襯積繭簾網網構齋) = 蓋網鬱窪製鑰選選觸製鏇壓遞構糧醖餘範膚糧 (醖遞憲憲網糧壓醖鹽夢 )
ASCO2007	临床1/2期	不能切除的胆道癌	22	Gemcitabine	(鬱鑰糧繭範簾蓋膚觸餘) = 繭範襯願窪觸鹹膚鏇獵醖觸夢蓋築顧觸夢淵顧 (膚網窪壓齋淵襯遞艱鬱 ) 更多	-	2007-06-20
				Octreotide/Imatinib	(鬱鑰糧繭範簾蓋膚觸餘) = 淵簾積淵窪願積網窪顧醖觸夢蓋築顧觸夢淵顧 (膚網窪壓齋淵襯遞艱鬱 ) 更多